EPSTEIN ROBERT S 4

What Happened Robert S. Epstein, a director of Veracyte, sold 10,000 shares of Veracyte common stock in an open-market transaction on May 20, 2026. The weighted average sale price was $44.01, producing gross proceeds of approximately $440,129. This was a sale (not a purchase); such transactions are often routine and may have been pre-scheduled.

Key Details

• Transaction date: May 20, 2026 (reported on Form 4 filed May 22, 2026).
• Sale details: 10,000 shares sold; weighted average price $44.01; sale prices ranged from $44.00 to $44.10.
• Proceeds: Approximately $440,129 (gross).
• Plan note: The sale was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Epstein on December 5, 2025 (pre-scheduled sale).
• Shares owned after transaction: Not specified in the provided filing summary.
• Timeliness: Form 4 filed May 22, 2026 — within the typical two-business-day filing window for Form 4s.

Context A Rule 10b5-1 plan lets insiders sell pre-specified amounts on a set schedule and is commonly used to avoid the appearance of trading on inside information; it generally indicates the trades were planned in advance rather than reactive. For retail investors, purchases typically carry more informational weight than routine sales, but this disclosure shows a director reduced holdings under a prearranged plan.